Independent information. England-wide.Public data. Clear sources.

NCT07662135 · Eluminate-4

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Registered research study with 6 identifiable England locations. See source dates, location-specific recruitment and the original study record.

Study facts

Conditions recorded
Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease
Lead sponsor
AstraZeneca
Study type
Interventional
Overall status
Recruiting · this can differ by location
Age range in the record
18 Years to Not specified
Sex eligibility field
All
Healthy volunteers accepted
No, according to the record
Phase
Phase3
Study record last updated
2 September 2026
Study team last verified status
2026-09

These fields are a starting point. Eligibility can include diagnosis, treatment history and other criteria shown only in the complete source record. A registry entry does not establish treatment effectiveness.

England study locations

A location is reproduced as named in the study record. A source map point can represent a town; it is not used here as a hospital entrance or to identify a care provider.

Location in the sourceLocal recruitment statusGeographic connection
Research Site

Blackpool · FY3 7EN

RecruitingCare in Blackpool

England postcode

Research Site

Hull · HU3 2JZ

Not yet recruitingCare in Kingston upon Hull

England postcode

Research Site

Penzance · TR18 3DX

Not yet recruitingCare in Cornwall

England postcode

Research Site

Sandbach · CW11 1EQ

RecruitingCare in Cheshire East

England postcode

Research Site

Thetford · IP24 1JD

RecruitingCare in Breckland

England postcode

Research Site

Whitney · OX29 4QB

Not yet recruitingCare in West Oxfordshire

England postcode

Questions for the research team

  • Is this exact location currently enrolling participants, and do my circumstances meet the full criteria?
  • What visits, tests, possible risks and follow-up would participation involve?
  • Are travel costs or accessibility arrangements available?
  • How would participation affect my usual care, and what happens if I withdraw?

Source: ClinicalTrials.gov, a United States Government database. Contains OS data © Crown copyright and database right 2026. Contains National Statistics data © Crown copyright and database right 2024; ONS country boundaries (December 2024).

Source processed: 2026-09-10 09:00:04 UTC. Retrieved: 10 September 2026. ClinicalTrials.gov terms.

How we selected and connected these records

Selected registered studies with an overall status of Recruiting or Not yet recruiting and at least one England location established by postcode, recorded nation, or source coordinates within the ONS December 2024 boundary. Retained structured fields; omitted descriptions, eligibility text, contacts and non-England locations. Deduplicated identical locations. Linked local care areas only by exact postcode geography. Location points are used for nation filtering, not directions or facility matching.